Shanthi Narla1, Jonathan I Silverberg2. 1. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Northwestern Medicine Multidisciplinary Eczema Center, Chicago, Illinois. Electronic address: JonathanISilverberg@gmail.com.
Abstract
BACKGROUND: Atopic dermatitis (AD) is associated with barrier disruption, immune dysregulation, and immunosuppressing treatments that can increase the association with an unusual number of infections. OBJECTIVE: To determine whether adults with AD have an unusually large number of serious infections and related outcomes. METHODS: Data from the 2002 to 2012 National Inpatient Sample were analyzed, including an approximately 20% sample of all US hospitalizations (n = 72,108,077 adults). Prevalence of serious infections in hospitalized patients with vs without AD, length of stay, cost of care, and inpatient mortality secondary to serious infections were determined. RESULTS: The prevalence of serious infections expressed as a percentage (95% confidence interval) was higher in adults hospitalized with than in those without AD (42.1% [41.6-42.6] vs 25.4% [25.2-25.6]; P = .0002). In logistic regression models with multiple predictors (multivariable logistic regression models), AD was associated with 32 of 38 infections examined. Associated cutaneous infections included eczema herpeticum (odds ratio [95% confidence interval] adjusted for other predictors: 67.93 [47.93-96.28]), erysipelas (11.15 [9.47-13.1]), and cellulitis (4.53 [4.42-4.64]). Associated respiratory infections included aspergillosis (1.51 [1.21-1.88]) and tuberculosis (1.57 [1.41-1.76]). AD was associated with extracutaneous, multiorgan, and systemic infections, including infectious arthropathy (2.01 [1.84-2.20]), endocarditis (1.25 [1.12-1.39]), encephalitis (1.65 [1.40-1.96]), and methicillin-resistant Staphylococcus aureus infections (3.29 [3.17-3.42]). Patients with AD hospitalized with vs without any serious infection had an increased geometric mean cost of inpatient care ($8,273 [8,126-8,423] vs $7,179 [7,052-7,307]) and length of stay (5.3 days [5.2-5.3] vs 3.9 [3.9-4.0]; P = .0002), with $11 to $228 million excess annual costs from hospitalization with serious infections in adults with AD. CONCLUSION: Adults with AD had increased cutaneous, respiratory, multiorgan, and systemic infections, which were associated with a considerable cost burden.
BACKGROUND:Atopic dermatitis (AD) is associated with barrier disruption, immune dysregulation, and immunosuppressing treatments that can increase the association with an unusual number of infections. OBJECTIVE: To determine whether adults with AD have an unusually large number of serious infections and related outcomes. METHODS: Data from the 2002 to 2012 National Inpatient Sample were analyzed, including an approximately 20% sample of all US hospitalizations (n = 72,108,077 adults). Prevalence of serious infections in hospitalized patients with vs without AD, length of stay, cost of care, and inpatient mortality secondary to serious infections were determined. RESULTS: The prevalence of serious infections expressed as a percentage (95% confidence interval) was higher in adults hospitalized with than in those without AD (42.1% [41.6-42.6] vs 25.4% [25.2-25.6]; P = .0002). In logistic regression models with multiple predictors (multivariable logistic regression models), AD was associated with 32 of 38 infections examined. Associated cutaneous infections included eczema herpeticum (odds ratio [95% confidence interval] adjusted for other predictors: 67.93 [47.93-96.28]), erysipelas (11.15 [9.47-13.1]), and cellulitis (4.53 [4.42-4.64]). Associated respiratory infections included aspergillosis (1.51 [1.21-1.88]) and tuberculosis (1.57 [1.41-1.76]). AD was associated with extracutaneous, multiorgan, and systemic infections, including infectious arthropathy (2.01 [1.84-2.20]), endocarditis (1.25 [1.12-1.39]), encephalitis (1.65 [1.40-1.96]), and methicillin-resistant Staphylococcus aureus infections (3.29 [3.17-3.42]). Patients with AD hospitalized with vs without any serious infection had an increased geometric mean cost of inpatient care ($8,273 [8,126-8,423] vs $7,179 [7,052-7,307]) and length of stay (5.3 days [5.2-5.3] vs 3.9 [3.9-4.0]; P = .0002), with $11 to $228 million excess annual costs from hospitalization with serious infections in adults with AD. CONCLUSION: Adults with AD had increased cutaneous, respiratory, multiorgan, and systemic infections, which were associated with a considerable cost burden.
Authors: Lisa A Beck; Mark Boguniewicz; Tissa Hata; Lynda C Schneider; Jon Hanifin; Rich Gallo; Amy S Paller; Susi Lieff; Jamie Reese; Daniel Zaccaro; Henry Milgrom; Kathleen C Barnes; Donald Y M Leung Journal: J Allergy Clin Immunol Date: 2009-06-27 Impact factor: 10.793
Authors: Robert Sidbury; Dawn M Davis; David E Cohen; Kelly M Cordoro; Timothy G Berger; James N Bergman; Sarah L Chamlin; Kevin D Cooper; Steven R Feldman; Jon M Hanifin; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Eric L Simpson; Wynnis L Tom; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Lawrence F Eichenfield Journal: J Am Acad Dermatol Date: 2014-05-09 Impact factor: 11.527
Authors: A Wollenberg; L A Beck; A Blauvelt; E L Simpson; Z Chen; Q Chen; B Shumel; F A Khokhar; T Hultsch; E Rizova; A B Rossi; N M H Graham; G Pirozzi; Y Lu; M Ardeleanu Journal: Br J Dermatol Date: 2019-12-01 Impact factor: 9.302
Authors: Sonal R Hattangdi-Haridas; Susan A Lanham-New; Wilfred Hing Sang Wong; Marco Hok Kung Ho; Andrea L Darling Journal: Nutrients Date: 2019-08-09 Impact factor: 5.717
Authors: Lawrence F Eichenfield; Thomas Bieber; Lisa A Beck; Eric L Simpson; Diamant Thaçi; Marjolein de Bruin-Weller; Mette Deleuran; Jonathan I Silverberg; Carlos Ferrandiz; Regina Fölster-Holst; Zhen Chen; Neil M H Graham; Gianluca Pirozzi; Bolanle Akinlade; George D Yancopoulos; Marius Ardeleanu Journal: Am J Clin Dermatol Date: 2019-06 Impact factor: 7.403
Authors: Łukasz Matusiak; Marta Szepietowska; Piotr K Krajewski; Rafał Białynicki-Birula; Jacek C Szepietowski Journal: Dermatol Ther Date: 2020-06-29 Impact factor: 2.851
Authors: Hai Le Thanh Nguyen; Juan Valentin Trujillo-Paez; Yoshie Umehara; Hainan Yue; Ge Peng; Chanisa Kiatsurayanon; Panjit Chieosilapatham; Pu Song; Ko Okumura; Hideoki Ogawa; Shigaku Ikeda; François Niyonsaba Journal: Int J Mol Sci Date: 2020-10-14 Impact factor: 5.923
Authors: H Alexander; A S Paller; C Traidl-Hoffmann; L A Beck; A De Benedetto; S Dhar; G Girolomoni; A D Irvine; P Spuls; J Su; J P Thyssen; C Vestergaard; T Werfel; A Wollenberg; M Deleuran; C Flohr Journal: Br J Dermatol Date: 2019-12-04 Impact factor: 9.302